Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease

Ähnliche Einträge

• Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
  von: Luis Antonio Díaz, et al.
  Veröffentlicht: (2025)
• Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
  von: Xing Bai, et al.
  Veröffentlicht: (2025)
• Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
  von: Maral Amangurbanova, et al.
  Veröffentlicht: (2024)
• Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
  von: Federica Tavaglione, et al.
  Veröffentlicht: (2025)
• Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
  von: Chia‐Chih Kuo, et al.
  Veröffentlicht: (2025)